Built for PSX investors
Follow live PSX prices, track holdings, read business news, and keep your watchlist close before the market moves.


LIVENLiven Pharma LtdLiven Pharma Limited announced condensed interim financial statements for the 3rd quarter ended March 31, 2026. Quarterly revenue nearly doubled year-on-year to Rs. 29.247 million, gross profit improved materially, and operating and net losses narrowed versus the same quarter last year. The company also disclosed that right shares were credited during the period, increasing paid-up share capital to 113,040,367 ordinary shares; no dividend was declared.
| Metric | PreviousMar 31, 2025 | CurrentMar 31, 2026 | Change |
|---|---|---|---|
| Revenue | 14,754,781 | 29,246,769 | +98.2% |
| Gross profit | 3,739,339 | 8,422,211 | +125.2% |
| Operating loss | (7,307,813) | (5,531,923) | +24.3% |
| Loss after taxation | (9,620,582) | (3,955,725) | +58.9% |
| Loss per share - basic and diluted | (0.10) | (0.03) | +70% |
| Finance cost | (11,834) | (258,012) | -2,080.4% |
| Cash and bank balances | 7,884,396 | 178,796,670 | +2,168.2% |
| Long term financing | 5,098,065 | 3,209,962 | -37% |
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.
Get Investify
The information on Investify is for informational purposes only and is not financial, investment, legal or tax advice. Market data, announcements, news, highlights, Buy/Sell/Neutral labels and other values may be sourced from or relate to Recube Technologies LLP, third-party providers and automated systems; none of these parties guarantees the timeliness, accuracy, completeness, correct sequencing, reliability or availability of such information. Nothing on the website or app is an offer, solicitation, recommendation or advice to buy, sell, hold or enter into any transaction. Investing involves risk, and users are responsible for verifying original sources and consulting qualified advisers before making investment decisions.
© 2026 Investify. All rights reserved.